États-Unis · Plateformes & données · MarketBeat

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Publié par MarketBeat · États-Unis il y a 2 h

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

À lire aussi

Anthropic's Revenue Surged to $16.3 Billion in the First Half of 2026, Up From $1.1 Billion a Year Ago

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Saudi Arabia intercepts Houthi missile as Trump threatens new strikes

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Electrolux (OM:ELUX B) Stock Can Q3 Results Turn EBIT Gains Into Profit?

Hooters closes 35-year-old location after shutting 55 restaurants

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Partager

À lire aussi

Anthropic's Revenue Surged to $16.3 Billion in the First Half of 2026, Up From $1.1 Billion a Year Ago

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Saudi Arabia intercepts Houthi missile as Trump threatens new strikes

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Electrolux (OM:ELUX B) Stock Can Q3 Results Turn EBIT Gains Into Profit?

Hooters closes 35-year-old location after shutting 55 restaurants